Scinai Immunotherapeutics (SCNI) versus Its Competitors Financial Review

Scinai Immunotherapeutics (NASDAQ:SCNI) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Scinai Immunotherapeutics to related businesses based on the strength of its earnings, analyst recommendations, valuation, profitability, dividends, institutional ownership and risk.

Valuation and Earnings

This table compares Scinai Immunotherapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31 million	-$8.31 million	0.05
Scinai Immunotherapeutics Competitors	$700.38 million	$9.44 million	-18.76

Scinai Immunotherapeutics’ peers have higher revenue and earnings than Scinai Immunotherapeutics. Scinai Immunotherapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Scinai Immunotherapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Scinai Immunotherapeutics Competitors	-12,319.70%	-407.93%	-30.95%

Analyst Recommendations

This is a summary of recent ratings for Scinai Immunotherapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Scinai Immunotherapeutics Competitors	9874	15295	45659	1600	2.54

As a group, “Biotechnology” companies have a potential upside of 126.22%. Given Scinai Immunotherapeutics’ peers stronger consensus rating and higher probable upside, analysts clearly believe Scinai Immunotherapeutics has less favorable growth aspects than its peers.

Volatility and Risk

Scinai Immunotherapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics’ peers have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.